Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DBD
DBD logo

DBD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
77.320
1 Day change
-0.44%
52 Week Range
84.460
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Diebold Nixdorf Inc (DBD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, and recent partnership with FOREX indicate a solid growth trajectory. While there is no immediate trading signal from Intellectia Proprietary Trading Signals, the technical indicators and positive sentiment from hedge funds support a buy decision.

Technical Analysis

The MACD is positive and expanding (0.23), indicating bullish momentum. The RSI is neutral at 59.405, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels (Pivot: 75.474, R1: 79.206), suggesting a stable upward trend.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • Strong Q4 financial performance with revenue up 11.66% YoY and net income up 785.71% YoY.

  • Positive analyst ratings with increased price targets to $100 from $

  • Recent partnership with FOREX to enhance ATM management across multiple countries, showcasing business expansion.

Neutral/Negative Catalysts

  • Insiders are selling, with a 113.75% increase in selling activity over the last month.

  • No recent congress trading data to validate political sentiment.

Financial Performance

In Q4 2025, Diebold Nixdorf reported a revenue increase of 11.66% YoY to $1.1042 billion, net income surged 785.71% YoY to $49.6 million, and EPS rose 813.33% YoY to 1.37. Gross margin also improved to 27.14%, up 13.51% YoY, indicating strong profitability and operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts from Wedbush and DA Davidson have raised their price targets to $100 from $80, maintaining Outperform and Buy ratings, respectively. Analysts are optimistic about the company's growth momentum and healthy order backlog.

Wall Street analysts forecast DBD stock price to rise
2 Analyst Rating
Wall Street analysts forecast DBD stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 77.660
sliders
Low
80
Averages
80
High
80
Current: 77.660
sliders
Low
80
Averages
80
High
80
Wedbush
Outperform
maintain
$80 -> $100
AI Analysis
2026-02-13
Reason
Wedbush
Price Target
$80 -> $100
AI Analysis
2026-02-13
maintain
Outperform
Reason
Wedbush raised the firm's price target on Diebold to $100 from $80 and keeps an Outperform rating on the shares. While broader markets were under pressure, Diebold reported strong Q4 results and 2026 guidance, with full year EPS of $5.50 exceeding consensus estimate of $4.87, the firm notes. Wedbush come out of earnings incrementally more positive, and expects the momentum the company enjoyed in 2025 will carry through 2026 with this year in many ways mirroring last.
DA Davidson
Matt Summerville
Buy
maintain
$80 -> $100
2026-02-13
Reason
DA Davidson
Matt Summerville
Price Target
$80 -> $100
2026-02-13
maintain
Buy
Reason
DA Davidson analyst Matt Summerville raised the firm's price target on Diebold to $100 from $80 and keeps a Buy rating on the shares. The company continues to experience healthy order entry and backlog, inclusive of 9 logos added within its growing North America Retail platform, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DBD
Unlock Now

People Also Watch